Population pharmacokinetics of oral busulfan in children

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 3, 2003, Pages 209-216

  Schiltmeyer, Brunhild ^a   Klingebiel, Thomas ^b   Schwab, Matthias ^c   Mürdter, Thomas E ^c   Ritter, Christoph A ^d   Jenke, Andreas ^e   Ehninger, Gerhard ^e   Gruhn, Bernd ^f   Würthwein, Gudrun ^a   Boos, Joachim ^a   Hempel, Georg ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Busulfan; Haematopoietic stem cell transplantation; NONMEM; Paediatrics; Population pharmacokinetics

Indexed keywords

BUSULFAN; GELATIN;

ANALYTICAL ERROR; ARTICLE; BLOOD SAMPLING; BODY SURFACE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; COVARIANCE; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PHOTOLYSIS; POPULATION MODEL; POPULATION RESEARCH; PRIORITY JOURNAL; SUSPENSION; TABLET;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BODY SURFACE AREA; BUSULFAN; CHILD; DOSAGE FORMS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 0141452188     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0631-y     Document Type: Article

References (35)

1. Blanz J, Rosenfeld C, Proksch B, Ehninger G, Zeller KP (1990) Quantitation of busulfan in plasma by high-performance liquid chromatography using postcolumn photolysis. J Chromatogr 532:429
2. Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, Galambrun C, Dai Q, Maire P, Jelliffe RW, Aulagner G (2001) Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 28:743
3. Boeckmann AJ, Sheiner LB, Beal SL (1992) NONMEM users guide. University of California at San Francisco
4. Bredschneider M, Klein K, Murdter TE, Marx C, Eichelbaum M, Nussler AK, Neuhaus P, Zanger UM, Schwab M (2002) Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin Pharmacol Ther 71:479
5. Buggia I, Zecca M, Alessandrino EP, Locatelli F, Rosti G, Bosi A, Pession A, Rotoli B, Majolino I, Dallorso A, Regazzi MB (1996) Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 16:2083
6. Cremers S, Schoemaker R, Bredius R, den Hartigh J, Ball L, Twiss I, Vermeij P, Vossen J (2002) Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 53:386
7. Filipovich AH, Shapiro RS, Ramsay NK, Kim T, Blazar B, Kersey J, McGlave P (1992) Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies. Blood 80:270
8. Fitzsimmons WE, Ghalie R, Kaizer H (1990) The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity. Cancer Chemother Pharmacol 27:226
9. Galimberti M, Polchi P, Lucarelli G, Delfini C, Politi P, Giardini C, Baronciani D, Manenti F (1987) Bone marrow transplantation in thalassemia after busulphan and cyclophosphamide. Report on 88 cases. Ann N Y Acad Sci 511:464
10. Geller RB, Dix SP (1999) Oral chemotherapy agents in the treatment of leukaemia. Drugs 58 [Suppl 3]:109
11. Geller RB, Vogelsang GB, Wingard JR, Yeager AM, Burns WH, Santos GW, Saral R (1988) Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease. J Clin Oncol 6:1558
12. Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, Slattery JT (1999) The impact of obesity and disease on busulfan oral clearance in adults. Blood 93:4436
13. Grochow LB (1993) Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20:18
14. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, Santos GW, Colvin OM (1989) Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25:55
15. Grochow LB, Krivit W, Whitley CB, Blazar B (1990) Busulfan disposition in children. Blood 75:1723
16. Hassan M, Oberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, Lonnerholm G, Smedmyr B, Taube A, Wallin I (1991) Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 28:130
17. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M (1993) Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 33:181
18. Hassan M, Svensson JO, Nilsson C, Hentschke P, Al-Shurbaji A, Aschan J, Ljungman P, Ringden O (2000) Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy. Ther Drug Monit 22:383
19. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Vogelsang GB, Sensenbrenner LL, Santos GW, Saral R (1987) Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 44:778
20. Karlsson MO, Sheiner LB (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21:735
21. Maschan AA, Kryzanovskii OI, Yourlova MI, Skorobogatova EV, Pashanov ED, Potapova YE, Timonova LA, Bogatcheva NY, Samochatova EV, Roumjantzev AG (1997) Intermediate-dose busulfan and cyclophosphamide as a conditioning regimen for bone marrow transplantation in a case of Fanconi anemia in myelodysplastic transformation. Bone Marrow Transplant 19:385
22. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA (1993) Venoocclusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118:255
23. Mürdter TE, Coller J, Claviez A, Schonberger F, Hofmann U, Dreger P, Schwab M (2001) Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry. Clin Chem 47:1437
24. Nevill TJ, Shepherd JD, Reece DE, Barnett MJ, Nantel SH, Klingemann HG, Phillips GL (1992) Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant 10:445
25. Nims RW, Prough RA, Jones CR, Stockus DL, Dragnev KH, Thomas PE, Lubet RA (1997) In vivo induction and in vitro inhibition of hepatic cytochrome P450 activity by the benzodiazepine anticonvulsants clonazepam and diazepam. Drug Metab Dispos 25:750
26. Ozsahin H, Le Deist F, Benkerrou M, Cavazzana-Calvo M, Gomez L, Griscelli C, Blanche S, Fischer A (1996) Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center. J Pediatr 129:238
27. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R (2001) Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos 29:264
28. Sandstrom M, Karlsson MO, Ljungman P, Hassan Z, Jonsson EN, Nilsson C, Ringden O, Oberg G, Bekassy A, Hassan M (2001) Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplant 28:657
29. Sano J, Kawada H, Yamaguchi N, Kawakita M, Kobayashi K (1981) Effects of phenytoin on serum gamma-glutamyl transpeptidase activity. Epilepsia 22:331
30. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner W, Bias WB, Braine HG, Burns WH, Elfenbein GJ, Kaizer H, Mellitis D, Sensenbrenner LL, Stuart RK, Yeager AM (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309:1347
31. Shaw PJ, Earl JW, Stevens MM, Bergin ME, Burgess M, Dalla Pozza L, Kellie SJ (1993) Pharmacokinetics of busulphan with single daily dosing during BMT conditioning with busulfan/cyclophosphamide (BUCY) for AML in children. Med Pediatr Oncol 21:539
32. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Appelbaum FR (1997) Marrow transplantation for chronic myeloic leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89:3055
33. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 79:2475
34. Vassal G, Fischer A, Challine D, Boland I, Ledheist F, Lemerle S, Vilmer E, Rahimy C, Souillet G, Gluckman E (1993) Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 82:1030
35. Yeager AM, Wagner JE, Graham ML, Jones RJ, Santos GW, Grochow LB (1992) Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 80:2425